New Cleveland Clinic CEO, pregnancy and IBD

The Cleveland Clinic has appointed colorectal surgeon Conor Delaney, MD, PhD, as the new CEO and president of the institution’s Florida region. It was the top story in gastroenterology last week.

Another top story was about a study that showed the risks of biologic therapy among pregnant women with inflammatory bowel disease (IBD) were comparable to risks among the general population.

Read these and more top stories in gastroenterology below:

Cleveland clinic names colorectal surgeon as new CEO, president of Florida region

As new president and CEO, Delaney will oversee five hospitals, a research center and outpatient centers that are affiliated with the Cleveland Clinic Florida region. Delaney is currently chairman of Cleveland Clinic’s Digestive Disease and Surgery Institute, where he is responsible for colorectal surgery, gastroenterology, hepatology, nutrition and general surgery. Read more.

Pregnancy and IBD: Biologic risks similar to general population

Adverse pregnancy outcomes among women with IBD on biologic therapy were comparable to that of the general population, according to study results. Read more.

Extended mirikizumab dose produces UC response in initial nonresponders

Additional extended treatment with mirikizumab (Eli Lilly) helped produce a clinical response in patients with ulcerative colitis who initially did not respond to treatment, according to study results. Read more.

Small intestine cells at risk for COVID-19 infection in IBD patients

High expression of ACE2 and TMPRSS2 in the small intestines may support gastrointestinal-correlated replication of SARS-COV-2, according to a study published in Gastroenterology. Read more.

Women more likely to have noncirrhotic HCC, underlying NAFLD

Compared with men, women had a significantly higher frequency of underlying nonalcoholic fatty liver disease and noncirrhotic hepatocellular carcinoma, according to data published in the American Journal of Gastroenterology. Read more.